Events and Presentations

June 2017
Cancer Targeted Technology company presentation. Beatrice Langton-Webster. BIO 2017.

June 2017
Comparison of a novel fluorine-18 labeled PSMA-targeting agent, 1057, to gallium-68 PSMA-11 patients with prostate cancer. Spencer Behr, Rahul Aggerwal, Robert Flavell, Thomas Hope, Kenneth Gao, Vahid Ravanfar, Youngho Seo, Beatrice Langton-Webster, Clifford Berkman and Henry VanBrocklin. Society of Nuclear Medicine and Molecular Imaging, Denver, CO.

June 2017
First-in-Human-PET studies with CTT1057, a novel fluorine-18 labeled agent targeting PSMA in prostate cancer. Spencer Behr, Rahul Aggerwal, Youngho Seo, Kenneth Gao, Vahid Ravanfar, James Slater, Salma Jivan, Joseph Blecha, Beatrice Langton-Webster, Clifford Berkman and Henry VanBrocklin. Society of Nuclear Medicine and Molecular Imaging, Denver, CO.

June 2017
First-in-Human-PET studies with CTT1057, a novel fluorine-18 labeled agent targeting PSMA in prostate cancer. Spencer Behr, Rahul Aggerwal, Youngho Seo, Kenneth Gao, Vahid Ravanfar, James Slater, Salma Jivan, Joseph Blecha, Beatrice Langton-Webster, Clifford Berkman and Henry VanBrocklin. Society of Nuclear Medicine and Molecular Imaging, Denver, CO.

June 2017
Comparison of traditional and albumin-binding Lu-177-labeled phosphoramidate-based PSMA inhibitors for targetedradionucleotide therapy of prostate cancer. Xiaoxi Ling, Cindy Choy, Jonathan Geruntho, Sophia Beyer, Joseph Latoche, Beatrice Langton-Webster, Carolyn Anderson and Clifford Berkman. Society of Nuclear Medicine and Molecular Imaging, Denver, CO.

April 2017
Improving the In Vitro and In Vivo Performance of a 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitor with an Albumin-Binding Motif. Choy, C.J.; Ling, X.; Geruntho, J.J.; Beyer, S.K.; Latoche, J.D.; Langton-Webster,B.; Anderson, C.J.; and Berkman. C.E. 253nd ACS National Meeting, San Francisco, CA.

June 2016
Cancer Targeted Technology company presentation. Beatrice Langton-Webster. BIO 2016.

June 2016
Cancer Targeted Technology company presentation. Beatrice Langton-Webster. Innovation Northwest.

June 2016
Development of a Novel PSMA-targeted PET Imaging Agent, CTT1057, for use in Prostate cancer. Beatrice Langton-Webster, Cliff Berkman, James Slater, Salma Jivan, Kiel Neumann, Elizabeth Whalley, Paul Ketteridge, Spencer Behr, Rahul Aggerwal and Henry VanBrocklin. Society of Nuclear Medicine and Molecular Imaging, San Diego, CA.

June 2016
Development and Safety of a Novel, Irreversibly-Binding PSMA-targeted Prosate Cancer Radiodiagnostic. Elizabeth Whalley, Clifford E. Berkman, Henry F VanBrocklin, Beatrice Langton-Webster. American Society of Clinical Oncology, Chicago, IL.

June 2014
Cancer Targeted Technology company presentation. Beatrice Langton-Webster. BIO 2014.

March 2010
Dr. Langton-Webster presented at the WBBA "Life Science Innovation Northwest" Conference in Seattle, WA.

February 2010
Fragmentation and nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase implicate initiation of apoptosis in prostate cancer cells following targeted photodynamic therapy. Tiancheng Liu, Lisa Y. Wu, Clifford E. Berkman. American Association for Cancer Research – Cell Death Mechanisms and Cancer Therapy. San Diego.

November 2009
Lysosome-targeted photodynamic therapy for prostate cancer cells with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen. Tiancheng Liu, Lisa Y. Wu and Clifford E. Berkman. American Association for Cancer Research – Molecular Targets and Cancer Therapeutics. Boston.

October 2009
Research in Prostate Cancer Detection and Treatment. Clifford E. Berkman and Paul Benny. Palouse Prostate Cancer Program, Pullman.

June 2009
Phosphoramidate peptidomimetics: A new class of PSMA inhibitors as PET agents for prostate Cancer. S. E. Lapi, H. Wahnishe, D. Pham, L. Wu, T. Liu, J. Nedrow-Byers, K. Vejdani, C. E. Berkman, H. F. VanBrocklin, E. F. Jones. Society of Nuclear Medicine Annual Meeting, Toronto Canada. A Targeted Approach to Prostate Cancer Imaging, Therapy, and Detection. Cliff Berkman. Invest Northwest, Seattle.

March 2009
Targeting Prostate Cancer with Chemoaffinity Agents. Clifford E. Berkman. Amgen, Seattle.

January 2009
Targeting Prostate Cancer with Chemoaffinity Agents. Clifford E. Berkman. Fred Hutchinson Cancer Research Center, Program in Prostate Cancer Research Seminar Series, Seattle.